Medifast Balance Sheet Health
Finanzielle Gesundheit Kriterienprüfungen 6/6
Medifast hat ein Gesamteigenkapital von $211.0M und eine Gesamtverschuldung von $0.0, wodurch sich der Verschuldungsgrad auf 0% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen $302.8M bzw. $91.8M. Medifast Das EBIT des Unternehmens beträgt $82.1M, so dass der Zinsdeckungsgrad -21.1 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von $156.4M.
Wichtige Informationen
0%
Verhältnis von Schulden zu Eigenkapital
US$0
Verschuldung
| Zinsdeckungsgrad | -21.1x |
| Bargeld | US$156.43m |
| Eigenkapital | US$210.96m |
| Gesamtverbindlichkeiten | US$91.80m |
| Gesamtvermögen | US$302.76m |
Jüngste Berichte zur Finanzlage
Recent updates
Medifast: GLP-1 Fears Are Overblown, But Proof Points For Turnaround Are Still Missing
Jun 26Medifast: Significant Undervaluation Even As Struggles Persist
May 24At US$22.76, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?
May 24
Lacklustre Performance Is Driving Medifast, Inc.'s (NYSE:MED) 32% Price Drop
May 24Medifast's (NYSE:MED) Conservative Accounting Might Explain Soft Earnings
May 06The Returns On Capital At Medifast (NYSE:MED) Don't Inspire Confidence
May 01Medifast: Cheap Valuation, Uncertain Future
Mar 20Medifast Is Getting Attractive
Mar 07Medifast, Inc.'s (NYSE:MED) 26% Dip In Price Shows Sentiment Is Matching Earnings
Feb 22Medifast Share Price Loses Weight, But Is There Still Value To Be Had?
Jan 20Are Investors Undervaluing Medifast, Inc. (NYSE:MED) By 47%?
Dec 09Medifast: Good On Paper, But A Slowdown In Sales Is Very Worrisome
Nov 24Is It Too Late To Consider Buying Medifast, Inc. (NYSE:MED)?
Nov 21Medifast: Unveiling A Challenge Beyond Weight Loss Drugs
Nov 09Medifast: The Race To Weight-Loss Drugs Not Lost Yet
Oct 09Medifast: Take Advantage Of Pessimism Over Weight Loss Drugs
Aug 04Is Now An Opportune Moment To Examine Medifast, Inc. (NYSE:MED)?
Jul 26In The Murky MLM Space, Medifast Might Actually Hold Some Promise
Jul 21Estimating The Intrinsic Value Of Medifast, Inc. (NYSE:MED)
Jul 05Medifast: In Survival Mode Against Diet Pills And The Recession
Jun 14Medifast Holds Value During Headwinds
May 28Medifast Non-GAAP EPS of $3.70 beats by $1.48, revenue of $337.2M beats by $7.1M
Feb 21Medifast: A Low Earnings Multiple Despite Strong Financial Performance
Feb 07At US$117, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?
Jan 19Medifast declares $1.64 dividend
Dec 08A Look At The Intrinsic Value Of Medifast, Inc. (NYSE:MED)
Dec 01Medifast's (NYSE:MED) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Nov 10One Medifast, Inc. (NYSE:MED) Analyst Just Made A Major Cut To Next Year's Estimates
Nov 08Medifast: This High-Yield Blue Chip Dividend Stock Is A Strong Buy
Nov 06What Does Medifast, Inc.'s (NYSE:MED) Share Price Indicate?
Oct 20We Think Medifast (NYSE:MED) Can Stay On Top Of Its Debt
Sep 18Medifast declares $1.64 dividend
Sep 08Do Medifast's (NYSE:MED) Earnings Warrant Your Attention?
Sep 02Medifast: Let's Dive Into Its Q2 Earnings And Assess The Bad And The Good
Aug 21Medifast, Inc. (NYSE:MED) Analysts Are Reducing Their Forecasts For This Year
Aug 09Are Medifast, Inc. (NYSE:MED) Investors Paying Above The Intrinsic Value?
Jul 27What Does Medifast, Inc.'s (NYSE:MED) Share Price Indicate?
Jul 12Medifast And Its Real Value
Jun 24Medifast: Growth And Value At A Reasonable Price
May 17Analyse der Finanzlage
Kurzfristige Verbindlichkeiten: MEDDie kurzfristigen Aktiva des Unternehmens ($219.6M) übersteigen seine kurzfristigen Passiva ($77.2M).
Langfristige Verbindlichkeiten: MEDDie kurzfristigen Vermögenswerte des Unternehmens ($219.6M) übersteigen seine langfristigen Verbindlichkeiten ($14.6M).
Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital
Verschuldungsgrad: MED ist schuldenfrei.
Schulden abbauen: MED hatte vor 5 Jahren keine Schulden.
Schuldendeckung: MED hat keine Schulden und muss daher nicht durch den operativer Cashflow gedeckt werden.
Zinsdeckung: MED hat keine Schulden, daher ist die Deckung der Zinszahlungen kein Problem.